| Literature DB >> 25936466 |
Claire Legendre1, Emmanuel Garcion2.
Abstract
Glioblastoma (GBM), the deadliest primary tumor of the central nervous system (CNS), is a clear illustration of the resistance of cancer cells to conventional therapies. Application of combinatorial strategies able to overcome pivotal factors of GBM resistance, particularly within the resection margins, represents an essential issue. This review focuses on the role of iron metabolism in GBM progression and resistance to therapy, and the impact of its pharmaceutical modulation on the disease. Iron, through its involvement in many biological processes, is a key factor in the control of cell behavior and cancer biology. Therefore, targeting cellular iron signaling or taking advantage of its dysregulation in cancer cells may lead to new opportunities for improving treatments and drug delivery in GBM.Entities:
Keywords: brain tumors; drug delivery; hypoxia; iron signaling; nanoparticles; radioresistance
Mesh：
Substances：
Year: 2015 PMID： 25936466 DOI： 10.1016/j.tem.2015.03.008
Source DB: PubMed Journal: Trends Endocrinol Metab ISSN： 1043-2760 Impact factor: 12.015